Plasma thrombin-activable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study - Monasterio, J; Bermúdez, P; Quiroga, D (Pathophysiol Haemost Thromb, 2004)
et al.